The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection (Q40113293)

17 September 2017

title

The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection (English)

1 reference

17 September 2017

7

Jay A Berzofsky

1 reference

17 September 2017

Antoun Toubaji

1

1 reference

17 September 2017

Sarah Hill

2

1 reference

17 September 2017

Masaki Terabe

3

1 reference

17 September 2017

Jiahua Qian

4

1 reference

17 September 2017

Tamara Floyd

5

1 reference

17 September 2017

R Mark Simpson

6

1 reference

17 September 2017

Samir N Khleif

8

1 reference

17 September 2017

language of work or name

English

0 references

publication date

12 June 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

25

1 reference

17 September 2017

issue

31

1 reference

17 September 2017

page(s)

5882-5891

1 reference

Tumor antigens recognized by T cells

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

7 January 2021

Cancer Tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Peptide vaccines for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Recent developments in adjuvants for vaccines against infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Cytokines and T cells in host defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Mechanisms of cytokine synergy essential for vaccine protection against viral challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Interleukin 2 signaling is required for CD4(+) regulatory T cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Tolerance, not immunity, crucially depends on IL-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Transient expression of interleukin 2 receptors. Consequences for T cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.040

10.1016/J.VACCINE.2007.05.040

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference